Glucagon-like peptide-1 (GLP-1) receptor agonists have brought a major shift in the management of diabetes mellitus (DM). Long-acting GLP-1 receptor agonists control glycemia better than short-acting agents and even better than insulin. These agents show cardioprotective and renoprotective effects and do not lead to weight gain or hypoglycemia. However, some dose-dependent adverse effects have been observed in clinical trials.
Analyzing the evidence regarding the benefits and adverse effects of GLP-1 receptor agonists can help clinicians deliver better care to DM patients. Join Dr. Supratik Bhattacharyya , an expert endocrinologist, in an exclusive session on “ GLP-1 Agonists in DM Management: Comparative Analysis ” on 27 th December 2022, 3:00 PM IST onwards. Stay Tuned for the Session!
